IMARC Group, a leading market research company, has recently releases report titled “Macular Degeneration Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global macular degeneration treatment market share, size, growth, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Industry Overview of Macular Degeneration Treatment
Macular degeneration is a medical condition that impacts the central part of the retina, which leads to loss of central vision. It can be caused by aging, genetic factors, smoking, and ultraviolet light exposure. It is associated with blurred or distorted central vision, difficulty in reading or recognizing faces, and dark spots in the central field of vision of an individual. It can be diagnosed by involving a comprehensive eye exam, which includes tests like visual acuity measurement, dilated eye exam, optical coherence tomography (OCT), and fluorescein angiography. It can be treated using medications, injections, and laser therapy, which aid in minimizing the pain associated with the symptoms.
How Big Is the Macular Degeneration Treatment Market?
The global macular degeneration treatment market size reached US$ 8.9 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.9 Billion by 2028, exhibiting a growth rate (CAGR) of 6.2% during 2023-2028.
Request Sample Copy of This Report: https://www.imarcgroup.com/macular-degeneration-treatment-market/requestsample
What are the growth prospects and trends in the macular degeneration treatment industry?
The increasing incidence of macular degeneration, especially among the aging population, represents one of the primary factors driving the demand for macular degeneration treatment around the world.
In addition, the rising public awareness campaigns about eye health and the easy availability of advanced diagnostic methods that allow for earlier detection of macular degeneration are favoring the growth of the market.
Apart from this, the launch of more effective and less invasive treatment options, such as anti-VEGF injections and ongoing research and development (R&D) activities to develop more innovative treatment approaches, is propelling the growth of the market.
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Type:
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
Breakup by Stage of Disease:
Early Stage
Intermediate Stage
Late Stage
Breakup by Route of Administration:
Intravenous Route
Intravitreal Route
Breakup by End User:
Hospitals
Ambulatory Surgical Center
Others
Breakup by Region:
North America: (United States, Canada)
Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163